Tudor Investment Corp ET AL Takes Position in Collegium Pharmaceutical, Inc. $COLL

Tudor Investment Corp ET AL bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,010 shares of the specialty pharmaceutical company’s stock, valued at approximately $560,000. Tudor Investment Corp ET AL owned approximately 0.05% of Collegium Pharmaceutical at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COLL. Federated Hermes Inc. boosted its position in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 350 shares during the period. Hantz Financial Services Inc. boosted its position in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the period. EverSource Wealth Advisors LLC boosted its position in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the period. NewEdge Advisors LLC boosted its position in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 2,294 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Collegium Pharmaceutical by 444.6% during the second quarter. Tower Research Capital LLC TRC now owns 3,551 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 2,899 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Barclays dropped their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Finally, Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.40.

Insiders Place Their Bets

In related news, EVP David Dieter sold 13,976 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the completion of the sale, the executive vice president directly owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at $2,900,225.70. The trade was a 41.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $34.93 on Thursday. The company has a market capitalization of $1.13 billion, a PE ratio of 20.43 and a beta of 0.77. The company has a 50 day simple moving average of $38.62 and a two-hundred day simple moving average of $41.52. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. Collegium Pharmaceutical, Inc. has a fifty-two week low of $25.86 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The firm had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.77 EPS. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.